Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy
Mavacamten therapy is safe and effective in the initiating phase. Determination of starting and maximum dose is based on <i>CYP2C19</i> metabolic status, while individualised dose adjustments are guided by echocardiographic response to optimise patient safety.
Authors
- Volker Rudolph (ORCID: https://orcid.org/0000-0001-5385-6839)
- Max Potratz (ORCID: https://orcid.org/0000-0003-4044-7037)
- Smita Scholtz (ORCID: https://orcid.org/0000-0002-7445-5986)
- Vasco Sequeira (ORCID: https://orcid.org/0000-0002-9192-7674)
- Jan‐Christian Reil (ORCID: https://orcid.org/0000-0003-1053-5175)
- Kawa Mohemed
- Werner Scholtz (ORCID: https://orcid.org/0009-0009-7495-9103)
- Cédric Coppée
Institutions
- Heart and Diabetes Center North Rhine-Westphalia (DE)
Publication Details
- Journal
- Open Heart
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/openhrt-2025-003192
- Citations
- 7
- Primary Topic
- Cardiomyopathy and Myosin Studies
- Type
- article
- Field-Weighted Citation Impact
- 9.72
Funders
- Deutsche Forschungsgemeinschaft
- Ruhr-Universität Bochum